|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
Survival Guide to FDA Inspections: Part 2, Conducting the Audit ? Ready or Not, Here They Come
Author(s)Massoud Lavian, Paul W. Allen
by Massoud Lavian and Paul W. Allen, Clarkston Consulting When an FDA inspection is imminent, it pays to have a plan. Start by getting your papers in order and your facility in a state of good repair. Train a team to manage interaction with inspectors. Coach your employees on how to answer questions. And don't forget to take notes.
Advertisement
Articles in this issue
over 23 years ago
FDA Launches Major CGMP Reviewover 23 years ago
Process Validation: How Much to Do and When to Do Itover 23 years ago
Biotech Will Recover!over 23 years ago
GMPs and Pharmaceutical Labelingover 23 years ago
Revolutionizing Biologics RegulationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5
